[go: up one dir, main page]

MX339277B - Agente inductor de inmunidad. - Google Patents

Agente inductor de inmunidad.

Info

Publication number
MX339277B
MX339277B MX2011001113A MX2011001113A MX339277B MX 339277 B MX339277 B MX 339277B MX 2011001113 A MX2011001113 A MX 2011001113A MX 2011001113 A MX2011001113 A MX 2011001113A MX 339277 B MX339277 B MX 339277B
Authority
MX
Mexico
Prior art keywords
polypeptide
immunity inducing
immunity inducer
immunity
seq
Prior art date
Application number
MX2011001113A
Other languages
English (en)
Other versions
MX2011001113A (es
Inventor
Fumiyoshi Okano
Masaki Shimizu
Takanori Saito
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2011001113A publication Critical patent/MX2011001113A/es
Publication of MX339277B publication Critical patent/MX339277B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un agente inductor de inmunidad, caracterizado porque comprende, como in ingrediente activo, por lo menos un polipéptido que tiene actividad inductora de inmunidad y que se selecciona de los siguientes polipéptidos (a), (b) y (c), o un vector recombinante que comprende un polinucleótido que codifica para el polipéptido y que es capaz de expresar el polipéptido in vivo: (a) el polipéptido consiste en la secuencia de aminoácidos que se muestra en cualquiera de SEQ ID Nos: 43 A 76 enumerada en el listado de secuencias; (b) un polipéptido que tiene 85% o más de identidad de secuencia con el polipéptido (a); y (c) un polipéptido de hasta 12 aminoácidos que comprende al polipéptido (a) o (b).
MX2011001113A 2008-08-05 2009-08-05 Agente inductor de inmunidad. MX339277B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008202065 2008-08-05
PCT/JP2009/063881 WO2010016525A1 (ja) 2008-08-05 2009-08-05 免疫誘導剤

Publications (2)

Publication Number Publication Date
MX2011001113A MX2011001113A (es) 2011-03-04
MX339277B true MX339277B (es) 2016-05-19

Family

ID=41663742

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015000895A MX348464B (es) 2008-08-05 2009-08-05 Agente inductor de inmunidad.
MX2011001113A MX339277B (es) 2008-08-05 2009-08-05 Agente inductor de inmunidad.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015000895A MX348464B (es) 2008-08-05 2009-08-05 Agente inductor de inmunidad.

Country Status (16)

Country Link
US (2) US8454968B2 (es)
EP (2) EP2837383B1 (es)
JP (2) JP5691171B2 (es)
KR (3) KR102009241B1 (es)
CN (2) CN102112146B (es)
AU (2) AU2009278385B2 (es)
BR (2) BRPI0912462B1 (es)
CA (1) CA2732283C (es)
DK (2) DK2837383T3 (es)
ES (2) ES2539603T3 (es)
HU (1) HUE031343T2 (es)
MX (2) MX348464B (es)
PL (2) PL2837383T3 (es)
PT (2) PT2837383T (es)
RU (2) RU2511039C2 (es)
WO (1) WO2010016525A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2498819C2 (ru) 2008-08-05 2013-11-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и профилактики злокачественных опухолей
JP5644110B2 (ja) 2008-08-05 2014-12-24 東レ株式会社 癌の検出方法
CN102821789B (zh) 2010-02-04 2016-03-02 东丽株式会社 癌的治疗和/或预防用药物组合物
CN102822199B (zh) * 2010-02-04 2014-10-15 东丽株式会社 癌的治疗和/或预防用药物组合物
HUE030102T2 (en) 2010-02-04 2017-04-28 Toray Industries A pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment and / or prevention of cancer
WO2011096535A1 (ja) * 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防のための医薬品
JP5906739B2 (ja) 2010-02-04 2016-04-20 東レ株式会社 癌の治療及び／又は予防用医薬組成物
PT2532365T (pt) * 2010-02-04 2016-07-28 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro
CA2836568C (en) * 2011-05-19 2020-07-21 Toray Industries, Inc. Immunity induction agent
ES2618026T3 (es) 2011-08-04 2017-06-20 Toray Industries, Inc. Composición farmacológica para el tratamiento y/o la prevención del cáncer
JP6094220B2 (ja) * 2011-08-04 2017-03-15 東レ株式会社 膵臓癌の検出方法
PL2740795T3 (pl) * 2011-08-04 2017-04-28 Toray Industries, Inc. Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
HUE030130T2 (en) 2011-08-04 2017-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of pancreatic cancer
JP6015448B2 (ja) * 2011-08-04 2016-10-26 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CN103717740B (zh) * 2011-08-04 2015-10-21 东丽株式会社 癌的治疗和/或预防用药物组合物
WO2013018891A1 (ja) * 2011-08-04 2013-02-07 東レ株式会社 癌の治療及び／又は予防用医薬組成物
PL2818483T3 (pl) 2012-02-21 2018-01-31 Toray Industries Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
PL2818482T3 (pl) 2012-02-21 2019-11-29 Toray Industries Kompozycja farmaceutyczna do leczenia nowotworu
KR102005308B1 (ko) 2012-02-21 2019-07-30 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
AU2013223147B2 (en) 2012-02-21 2017-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
AU2013241036B2 (en) * 2012-03-30 2017-07-20 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
PL2832366T3 (pl) * 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego
PT2876446T (pt) 2012-07-19 2019-03-25 Toray Industries Método para deteção de cancro
BR112015001100A2 (pt) 2012-07-19 2018-03-27 Toray Industries, Inc. método de detecção de câncer
TR201819812T4 (tr) 2013-08-09 2019-01-21 Toray Industries Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim
MX2017013473A (es) * 2015-04-30 2017-12-07 Toray Industries Agente inductor de inmunidad.
JP7206590B2 (ja) * 2016-10-28 2023-01-18 東レ株式会社 癌の治療及び／又は予防用医薬組成物
US20210121562A1 (en) * 2018-03-30 2021-04-29 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN109206501B (zh) * 2018-09-26 2022-03-04 东北农业大学 猫干扰素ω、其编码基因及其在抗病毒方面的应用
CN109206502B (zh) * 2018-09-26 2022-03-04 东北农业大学 一种猫干扰素ω及其制备方法和在抗病毒中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
EP1870466A3 (en) * 1998-07-14 2008-03-19 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2002083070A2 (en) * 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US20030190640A1 (en) * 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
MXPA04003901A (es) * 2001-11-07 2004-07-08 Cytos Biotechnology Ag Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas.
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2007095186A2 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
KR20080075722A (ko) 2007-02-13 2008-08-19 엘지이노텍 주식회사 튜너
JP4826496B2 (ja) 2007-02-16 2011-11-30 三菱マテリアル株式会社 電解メッキ用アノード電極取付構造
WO2013143026A1 (en) * 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
WO2014197471A1 (en) * 2013-06-03 2014-12-11 Acetylon Pharmaceuticals, Inc. Histone deacetylase ( hdac) biomarkers in multiple myeloma

Also Published As

Publication number Publication date
AU2015210461B2 (en) 2017-07-13
KR102009241B1 (ko) 2019-08-09
CN102112146B (zh) 2014-03-12
KR20170128637A (ko) 2017-11-22
PL2324842T3 (pl) 2015-08-31
RU2511039C2 (ru) 2014-04-10
CA2732283A1 (en) 2010-02-11
EP2324842A4 (en) 2012-05-23
KR20160127146A (ko) 2016-11-02
EP2324842B1 (en) 2015-03-25
KR20110044854A (ko) 2011-05-02
AU2009278385B2 (en) 2015-06-11
BRPI0912462A2 (es) 2016-02-02
CN103751771A (zh) 2014-04-30
US20110123492A1 (en) 2011-05-26
EP2837383A1 (en) 2015-02-18
KR101669827B1 (ko) 2016-10-27
JP5691171B2 (ja) 2015-04-01
DK2837383T3 (en) 2017-03-20
US9592281B2 (en) 2017-03-14
RU2013156620A (ru) 2015-06-27
MX2011001113A (es) 2011-03-04
MX348464B (es) 2017-06-14
CN102112146A (zh) 2011-06-29
RU2011108315A (ru) 2012-09-10
JPWO2010016525A1 (ja) 2012-01-26
CA2732283C (en) 2017-12-05
BR122020027042B1 (pt) 2022-11-08
JP2015061847A (ja) 2015-04-02
EP2324842A1 (en) 2011-05-25
BRPI0912462B1 (pt) 2022-03-22
PT2324842E (pt) 2015-07-21
WO2010016525A1 (ja) 2010-02-11
AU2015210461A1 (en) 2015-09-03
PT2837383T (pt) 2017-03-17
ES2539603T3 (es) 2015-07-02
AU2009278385A1 (en) 2010-02-11
CN103751771B (zh) 2017-09-08
DK2324842T3 (da) 2015-06-22
EP2837383B1 (en) 2016-12-14
ES2619322T3 (es) 2017-06-26
HUE031343T2 (hu) 2017-07-28
US20130230488A1 (en) 2013-09-05
RU2639518C2 (ru) 2017-12-21
JP5962739B2 (ja) 2016-08-03
US8454968B2 (en) 2013-06-04
PL2837383T3 (pl) 2017-07-31

Similar Documents

Publication Publication Date Title
MX339277B (es) Agente inductor de inmunidad.
ES2565060T3 (es) Polipéptidos que tienen actividad de glucoamilasa y polinucleótidos que codifican los mismos
ECSP15042898A (es) Péptidos y composiciones para el tratamiento de daño articular
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
MX2024015050A (es) L-asparaginasa modificada
HN2009001593A (es) Coagnistas de receptor de glucagon/glp-1
PE20191203A1 (es) Variantes de alfa-glucosidasa acida y usos de las mismas
ES2691539T3 (es) Luciferasas de Oplophorus sintéticas con mayor emisión de luz
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
PH12013500050A1 (en) Anticancer fusion protein
CR20150196A (es) Moléculas de unión il-17a novedosas y usos médicos de las mismas
CO6430475A2 (es) Polipéptidos que tienen actividad de celulasa
PE20140617A1 (es) Alfa glucosidasa acida modificada con procesamiento acelerado
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
GT201700224A (es) Proteína de unión a rgma y su uso
MX2010002018A (es) Peptido de cdh3 y agente medicinal que comprende al mismo.
EA201990856A1 (ru) Новые противомикробные агенты против бактерий enterococcus
AR071534A1 (es) Peptidos aislados que tienen actividad inhibitoria de la fosfolipasa
MX344183B (es) Proteina antimicrobiana.
ES2536238T3 (es) Péptidos antimicrobianos
ES2633468T3 (es) Agente inductor de inmunidad y método para la detección del cáncer
MY171183A (en) Polypeptide glycosylated with sialylated sugar chain
MX2018001298A (es) Agente inductor de inmunidad.
BR112013002702A2 (pt) vacina

Legal Events

Date Code Title Description
FG Grant or registration